House Dems seek brief­in­gs with Pfiz­er, San­doz and Te­va on on­go­ing drug short­ages

Last year
Pharma
FDA+

Eli Lil­ly backs women’s health group­s' cam­paign to spur obe­si­ty treat­ment cov­er­age

Last year
Pharma
Marketing

MD An­der­son buys tech from Bel­licum; Tar­sus’ Ly­me dis­ease tri­al da­ta; Rigel takes Gavre­to

Last year
News Briefing

Amy­lyx’s ALS drug tastes bit­ter. What would make it bet­ter? More patent life

Last year
R&D
Pharma

Space man­u­fac­tur­ing re­turns to Earth; Charles Riv­er ex­pands an­ti­body man­u­fac­tur­ing of­fer­ings

Last year
Manufacturing

Like Gilead, Ab­b­Vie gets its ten­ta­cles in­to pact with Ten­tar­ix

Last year
Startups
Deals

Si­mone Song's ORI Cap­i­tal clos­es $260M sec­ond fund af­ter CG On­col­o­gy suc­cess

Last year
Financing
Startups

Mod­er­na’s ‘year of tran­si­tion’: Chang­ing gears from Covid-19 to RSV as vac­cine ap­proval date looms

Last year
R&D
Pharma

Re­searchers de­tail da­ta from first 15 au­toim­mune dis­ease pa­tients treat­ed with CAR-T — and out­stand­ing ques­tions

Last year
R&D
Cell/Gene Tx

No­vavax and Gavi set­tle over Covid-19 vac­cine part­ner­ship dis­pute 

Last year
Deals
Manufacturing

Teladoc is­n't ex­pect­ing to grow as fast as in­vestors ex­pect­ed, cast­ing a cloud on the fu­ture of tele­health

Last year
Health Tech

Unit­ed Ther­a­peu­tics sues FDA over han­dling of Liq­uidia’s new drug ap­pli­ca­tion for tre­pros­tinil

Last year
Pharma
FDA+

Adap­tive Biotech­nolo­gies trims hand­ful of jobs as strate­gic re­view nears com­ple­tion

Last year
People

House De­moc­rats re­it­er­ate call for FDA to work on clin­i­cal di­ver­si­ty ac­tion plans

Last year
Pharma
FDA+

First Keytru­da biosim­i­lars move in­to clin­i­cal tri­als as Mer­ck push­es ahead with new for­mu­la­tion

Last year
Pharma

Is a mail­box an of­fice? Not ac­cord­ing to the US' bank­rupt­cy ar­gu­ment against Sor­ren­to Ther­a­peu­tics

Last year
Pharma
Law

J&J so­cial me­dia pro­gram aims to add more di­verse voic­es in lung can­cer ad­vo­ca­cy

Last year
Pharma
Marketing

SCO­TUS jus­tices hint at un­cer­tain fu­ture of Chevron doc­trine in tan­gen­tial case

Last year
FDA+
Law

Af­ter No­var­tis’ Adakveo was pulled in Eu­rope, the UK fol­lows suit 

Last year
Pharma

The top 100 ven­ture play­ers in bio­phar­ma to­day. Who's in? What's out?

Last year
Financing
Bioregnum

Emer­gent calls on new CEO Joe Pa­pa to lead turn­around fol­low­ing pan­dem­ic stum­bles

Last year
People
Pharma

New dose sched­ule for J&J bis­pe­cif­ic; Lay­offs at Ring Ther­a­peu­tics; Re­gen­eron’s pri­or­i­ty re­view

Last year
News Briefing

Bavar­i­an Nordic drops can­cer vac­cine ef­forts to fo­cus on in­fec­tious dis­eases

Last year
R&D

Vi­iV's long-act­ing Cabe­nu­va beats out dai­ly oral HIV treat­ments in PhI­II

Last year
R&D
Pharma
First page Previous page 196197198199200201202 Next page Last page
A service from the Financial Times